Rentschler Biopharma SE, a global contract development and manufacturing organization (CDMO) for biopharmaceuticals, and XL-protein GmbH, a privately owned biopharmaceutical company located in Germany, have entered a collaboration to manufacture a long-acting, hyperactive recombinant human deoxyribonuclease I (DNase I).   Combining XL-protein’s proprietary PASylation technology and Rentschler Biopharma’s expertise in bioprocess development, a process was developed with enhanced yield for a mod...